Aktieanalys

Moberg Pharma: The Swedish market leader - Redeye

Redeye Publicerad: 14 Aug 08:09

Redeye views the Q2 report as further confirmation of a successful strategy to already arrive at being the Swedish market leader. The better sales than expected in the quarter are, of course, positive in themselves and solidify our view that the strategy taken by Moberg Pharma is solid. We adjusted our expectations slightly upwards for 2024/2025e as the market impact of Terclara on the market has been substantial, and we also deduced that the deal with Allderma was better than we had accounted for. The Base case is SEK 32(29) per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/1029478/moberg-pharma-the-swedish-market-leader?utm_source=finwire&utm_medium=RSS

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!